Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
92 studies found for:    Open Studies | "Dry Eye Syndromes"
Show Display Options
Rank Status Study
1 Recruiting Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
Condition: Dry Eye Syndrome
Interventions: Drug: RGN-259;   Drug: Placebo
2 Not yet recruiting Effect of Nursing Care on Prevention of Dry Eye
Condition: Dry Eye Syndromes
Interventions: Device: LACRIBELL®;   Device: VIDISIC® GEL;   Drug: 0,9% saline
3 Not yet recruiting Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Condition: Dry Eye Syndromes
Interventions: Drug: AGN-195263;   Drug: Vehicle
4 Recruiting Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Condition: Dry Eye Syndromes
Interventions: Drug: AGN-195263;   Drug: Vehicle
5 Recruiting Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome
Condition: Dry Eye Syndrome
Interventions: Device: T2762;   Device: Optive
6 Recruiting Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome
Condition: Dry Eye Syndrome
Interventions: Drug: HU00701;   Drug: HU007;   Drug: Restasis;   Drug: Placebo
7 Not yet recruiting Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction
Condition: Dry Eye Syndrome
Interventions: Device: intense pulsed light;   Drug: Tobramycin and Dexamethasone Ophthalmic Ointment
8 Not yet recruiting Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients
Condition: Dry Eye Syndromes
Interventions: Drug: Prosicca;   Drug: Prosicca sine;   Other: Bacterial culture
9 Not yet recruiting A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
Condition: Dry Eye Syndromes
Interventions: Drug: Omega 3;   Drug: Optive Advanced;   Drug: Optive
10 Recruiting DNase Treatment for Dry Eyes
Condition: Dry Eye
Interventions: Drug: DNase;   Drug: Vehicle
11 Recruiting Study to Evaluate the Efficacy and Safety of CKD-350
Condition: Dry Eye Syndrome
Interventions: Drug: Xenobella;   Drug: Isotonic 0.3% Sodium Hyaluronate
12 Recruiting 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
Conditions: Dry Eye Syndromes;   Diabetes Mellitus
Intervention: Drug: 0.3% Sodium Hyaluronate
13 Recruiting Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
14 Recruiting Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Conditions: Dry Eye Syndromes;   Keratoconjunctivitis Sicca
Interventions: Drug: KPI-121 0.25% Ophthalmic Suspension;   Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension
15 Recruiting Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
Condition: Dry Eye
Interventions: Drug: Pregabalin;   Drug: Placebo
16 Recruiting Dry Eye Assessment and Management Study
Condition: Dry Eye
Interventions: Drug: Omega-3 supplements;   Drug: Placebo
17 Recruiting Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome
Condition: Dry Eye Syndromes
Interventions: Device: Thealoz Duo eye drops and Thealoz Duo gel;   Device: Thealoz Duo gel
18 Recruiting Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome
Condition: Dry Eye Syndromes
Interventions: Device: Thealoz Duo Eye Drops;   Device: Optive Eye Drops;   Device: Systane Ultra Eye Drops
19 Recruiting Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye
Condition: Dry Eye Syndromes
Interventions: Device: REMOGEN OMEGA;   Device: Povidone
20 Recruiting Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
Condition: Dry Eye Syndromes
Interventions: Drug: Placebo;   Other: Sham;   Drug: Cyclosporine New Ophthalmic Formulation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.